Results 41 to 50 of about 6,009 (196)

In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis [PDF]

, 2013
BACKGROUND: The APOE4 allele variant is the strongest known genetic risk factor for developing late-onset Alzheimer’s disease. The link between apolipoprotein E (apoE) and Alzheimer’s disease is likely due in large part to the impact of apoE on the ...
Burchett, Jack M, Castellano, Joseph M, Cirrito, John R, Holtzman, David M, Jiang, Hong, Landreth, Gary E, Mahan, Thomas E, Restivo, Jessica L, Schuler, Dorothy R, Ulrich, Jason D, Verghese, Philip B   +10 more
core   +2 more sources

Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy

Case Reports in Oncology, 2018
Bexarotene is a third-generation retinoid X receptor-selective retinoid that is widely used for the early treatment of advanced-stage cutaneous T-cell lymphomas.
Yota Sato, Taku Fujimura, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba   +4 more
doaj   +1 more source

Rapidly Progressive Multiple Skin Plaques and Nodules: A Quiz

Acta Dermato-Venereologica, 2023
is missing (Quiz)
Hikari Boki, Tomomitsu Miyagaki, Hiraku Suga, Hanako Ohmatsu, Shinichi Sato   +4 more
doaj   +1 more source

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18:Nuclear hormone receptors [PDF]

, 2017
The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and ...
,, Alexander, Stephen Ph, Cidlowski, John A, Davies, Jamie A, Faccenda, Elena, Harding, Simon D, Kelly, Eamonn, Marrion, Neil V, Pawson, Adam J, Peters, John A, Sharman, Joanna L, Southan, Christopher   +11 more
core   +5 more sources

Categorization of Reasons for Hospitalizations in Patients With Cutaneous T‐Cell Lymphoma

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Cutaneous T‐cell lymphomas (CTCL) can significantly impact patients' quality of life as well as impose a substantial healthcare burden due to their complex management and risk of hospitalization. Objectives This study aimed to identify factors associated with hospital admissions among patients with CTCL and to characterize the ...
Geetha Gowda, Sowmya Ravi, Maxwell Green, Caroline Power, Kendall McDaniel, Erin Boh, Carole Bitar   +6 more
wiley   +1 more source

Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARγ/SIRT6/FoxO3a pathway after subarachnoid hemorrhage in rats

Journal of Neuroinflammation, 2019
Background Subarachnoid hemorrhage (SAH) is a life-threatening subtype of stroke with high mortality and disabilities. Retinoid X receptor (RXR) has been shown to be neuroprotective against ischemia/reperfusion injury. This study aimed to investigate the
Yuchun Zuo, Lei Huang, Budbazar Enkhjargal, Weilin Xu, Ocak Umut, Zachary D. Travis, Guangyu Zhang, Jiping Tang, Fei Liu, John H. Zhang   +9 more
doaj   +1 more source

Dichloro[N-[(η⁶-phenyl)methyl]-4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8tetrahydronaphthalen-2-yl)vinyl)benzamide](1,3,5-triaza-7-phosphatricyclo [3.3.1.1^3,7]decane-κP⁷)ruthenium

Molbank, 2022
Bexarotene-tethered RuII(arene) compounds with 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (PTA) were prepared as an analog of RAPTA antitumor complexes in order to evaluate their in vitro antiproliferative activity against human cancer cell lines.
Ilya A. Shutkov, Dmitrii M. Mazur, Nataliya E. Borisova, Elena R. Milaeva, Alexey A. Nazarov   +4 more
doaj   +1 more source

The Concise Guide to PHARMACOLOGY 2015/16:Nuclear hormone receptors [PDF]

, 2015
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org),
Aldrich, R, Alexander, SPH, Attali, B, Back, M, Barnes, NM, Bathgate, R, Beart, PM, Becirovic, E, Benson, HE, Biel, M, Birdsall, NJ, Boison, D, Brauner-Osborne, H, Broeer, S, Bryant, C, Burnstock, G, Burris, T, Cain, D, Calo, G, Chan, SL, Chandy, KG, Chiang, N, Christakos, S, Christopoulos, A, Chun, JJ, Chung, J-J, Cidlowski, JA, Clapham, DE, Connor, MA, Coons, L, Cox, HM, Dautzenberg, FM, Davies, JA, Dent, G, Douglas, SD, Dubocovich, ML, Edwards, DP, Faccenda, E, Farndale, R, Fong, TM, Forrest, D, Fowler, CJ, Fuller, P, Gainetdinov, RR, Gershengorn, MA, Goldin, A, Goldstein, SAN, Grimm, SL, Grissmer, S, Gundlach, AL, Hagenbuch, B, Hammond, JR, Hancox, JC, Hartig, S, Hauger, RL, Hay, DL, Hebert, T, Hollenberg, AN, Holliday, ND, Hoyer, D, Ijzerman, AP, Inui, KI, Ishii, S, Jacobson, KA, Jan, LY, Jarvis, GE, Jensen, R, Jetten, A, Jockers, R, Kaczmarek, LK, Kanai, Y, Kang, HS, Karnik, S, Kelly, E, Kerr, ID, Korach, KS, Lange, CA, Larhammar, D, Leeb-Lundberg, F, Leurs, R, Lolait, SJ, Macewan, D, Maguire, JJ, Marrion, N, May, JM, Mazella, J, McArdle, CA, McDonnell, DP, Michel, MC, Miller, LJ, Mitolo, V, Monie, T, Monk, PN, Mouillac, B, Murphy, PM, Nahon, J-L, Nerbonne, J, Nichols, CG, Norel, X, Oakley, R, Offermanns, S, Palmer, LG, Panaro, MA, Pawson, AJ, Perez-Reyes, E, Pertwee, RG, Peters, JA, Pike, JW, Pin, JP, Pintor, S, Plant, LD, Poyner, DR, Prossnitz, ER, Pyne, S, Ren, D, Richer, JK, Rondard, P, Ross, RA, Sackin, H, Safi, R, Sanguinetti, MC, Sartorius, CA, Segaloff, DL, Sharman, JL, Sladek, FM, Southan, C, Stewart, G, Stoddart, LA, Striessnig, J, Summers, RJ, Takeda, Y, Tetel, M, Toll, L, Trimmer, JS, Tsai, M-J, Tsai, SY, Tucker, S, Usdin, TB, Vilargada, J-P, Vore, M, Ward, DT, Waxman, SG, Webb, P, Wei, AD, Weigel, N, Willars, GB, Winrow, C, Wong, SS, Wulff, H, Ye, RD, Young, M, Zajac, J-M   +151 more
core   +4 more sources

Brentuximab Vedotin‐Induced Rash Sparing CD30‐Positive Mycosis Fungoides Lesions

JEADV Clinical Practice, EarlyView.
ABSTRACT Brentuximab vedotin (BV) is an effective treatment for CD30‐positive lymphomas, including mycosis fungoides (MF). However, its use can be associated with various cutaneous adverse effects, including rashes. This case describes a 60‐year‐old male with stage IIB MF who developed a drug‐induced erythematous rash after three infusions of BV ...
Isabel Hariri, Alexander H. Enk, Jessica C. Hassel   +2 more
wiley   +1 more source

Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses

Acta Dermato-Venereologica, 2022
is missing (Short communication)
Jacques Rouanet, Ines Joulie, Celine Lambert, Michel D'Incan   +3 more
doaj   +1 more source